Edwards Lifesciences Corporation (EW) Stock Price & Analysis
Edwards Lifesciences Corporation (EW) closed at USD 90.09 on Thursday, October 22, 2026, up 1.91% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 88.4; the Oct 22, 2026 session ranged USD 88.28–90.18 on volume of 3,054,068 shares. Market capitalization is $51.93B, with a 52-week range of USD 74.66–96.29 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EW.md
Key facts (EW)
- Last four reported quarters (through Jun 30, 2026): revenue $6.51B, net income $1.00B (15.4% margin), free cash flow $1.43B (SEC filings).
- Valuation: P/E 51.7x (avg 30.1x at the last 3 fiscal year-ends), EV/EBITDA 29.9x, net cash $3.65B.
- 2 of 80 tracked superinvestors hold EW (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 23 Form 4 filings, $12.6M; 12 not under a Rule 10b5-1 plan ($8.1M); 0 by opportunistic insiders, 5 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.07 on a 1–5 scale) (30 analysts), mean target USD 101.39 (range 84–110).
- Total return with dividends: 1Y +17.7% vs S&P 500 +14.9%; 5Y -22.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 0.74, revenue estimate $1.68B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (EW)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $5.23B | $4.46B | $5.01B | $5.44B | $6.07B | $6.51B |
| Gross profit | $3.98B | $3.74B | $4.03B | $4.32B | $4.73B | — |
| Operating income | $1.69B | $1.50B | $1.31B | $1.38B | $1.26B | $1.45B |
| Net income | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B | $1.00B |
| EPS (diluted) | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 | — |
| Free cash flow | $1.41B | $974M | $643M | $290M | $1.33B | $1.43B |
| Gross margin | 76.1% | 83.8% | 80.5% | 79.5% | 78.0% | — |
| Operating margin | 32.3% | 33.6% | 26.1% | 25.3% | 20.8% | 22.3% |
| Net margin | 28.7% | 34.1% | 28.0% | 76.7% | 17.7% | 15.4% |
| Revenue growth | +19.3% | -14.7% | +12.2% | +8.6% | +11.5% | — |
| Cash + short-term investments | $1.47B | $1.22B | $1.63B | $3.98B | $4.23B | — |
| Total debt | $596M | $596M | $597M | $598M | $598M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (EW)
P/E 51.7x · P/S 8.0x · EV/EBITDA 29.9x · EV/Sales 7.4x · P/FCF 36.2x · P/B 4.9x · FCF yield 2.76% · Earnings yield 1.94% · Buyback yield (TTM) 2.32% · Net cash $3.65B · EV $48.3B
P/E at fiscal year-ends: Dec 2025 46.5x, Dec 2024 10.6x, Dec 2023 33.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (EW)
2 of 80 tracked investors hold EW. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Rolfe | Wedgewood Partners | 3.08% | $14.9M | Reduced -3.4% |
| Torray Funds | 0.04% | $271K | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (EW)
11 of 23 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Lippis Daniel J. | CVP, TAVR | 619 | $53K | 1.5% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023) |
| 2026-09-11 | Lippis Daniel J. | CVP, TAVR | 619 | $54K | 1.5% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023) |
| 2026-08-31 | Dahl Andrew M. | SVP, Corporate Controller | 544 | $50K | 3.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-28 | Bruls Annette | CVP, EMEACLA | 2,644 | $238K | 12.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-26 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | 31,800 | $2.9M | 41.8% | No | Routine (sold in Aug & Dec each year 2023–2025) |
| 2026-08-26 | Markowitz Wayne | CVP, JAPAC | 1,240 | $113K | 5.8% | No | Too little history (no open-market trades in 2023) |
| 2026-08-11 | Lippis Daniel J. | CVP, TAVR | 619 | $57K | 1.5% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023) |
| 2026-07-30 | Markowitz Wayne | CVP, JAPAC | 146 | $13K | 0.7% | No | Too little history (no open-market trades in 2023) |
| 2026-07-28 | Markowitz Wayne | CVP, JAPAC | 9,628 | $819K | 30.8% | No | Too little history (no open-market trades in 2023) |
| 2026-07-27 | Zovighian Bernard J | CEO | 2,921 | $245K | 2.6% | No | Too little history (no open-market trades in 2023) |
| 2026-07-10 | Lippis Daniel J. | CVP, TAVR | 619 | $57K | 1.5% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023) |
| 2026-06-30 | Lippis Daniel J. | CVP, TAVR | 619 | $57K | 1.5% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023) |
| 2026-06-17 | Zovighian Bernard J | CEO | 523 | $46K | 0.5% | Yes (adopted December 12, 2025) | Too little history (no open-market trades in 2023) |
| 2026-05-29 | Dahl Andrew M. | SVP, Corporate Controller | 568 | $49K | 3.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-27 | Bobo Donald E Jr | CVP,Strategy/Corp Development | 23,145 | $2.0M | 13.2% | No | Routine (sold in Jan & Feb & Mar & Apr & Jun & Dec each year 2023–2025; this trade is outside those months) |
| 2026-05-22 | Chopra Daveen | CVP, TMTT & Surgical | 1,500 | $127K | 3.3% | No | Routine (sold in Aug & Dec each year 2023–2025; this trade is outside those months) |
| 2026-05-18 | Lippis Daniel J. | CVP, TAVR | 620 | $50K | 1.5% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023) |
| 2026-05-15 | Bobo Donald E Jr | CVP,Strategy/Corp Development | 17,968 | $1.5M | 9.3% | No | Routine (sold in Jan & Feb & Mar & Apr & Jun & Dec each year 2023–2025; this trade is outside those months) |
| 2026-05-12 | Zovighian Bernard J | CEO | 36,351 | $2.8M | 24% | Yes (adopted December 12, 2025) | Too little history (no open-market trades in 2023) |
| 2026-05-11 | Markowitz Wayne | CVP, JAPAC | 593 | $47K | 2.7% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (EW)
Consensus Buy (mean 2.07 on a 1–5 scale), 30 analysts; mean target USD 101.39 (low 84, high 110).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Overweight | $110 |
| 2026-09-11 | BTIG | Reiterated | Buy | $110 |
| 2026-07-25 | Leerink Partners | Upgrade | Market Perform → Outperform | $87 → $101 |
| 2026-07-24 | JP Morgan | Target raised | Overweight | $100 → $105 |
| 2026-07-24 | Piper Sandler | Target raised | Overweight | $100 → $101 |
| 2026-07-16 | Truist Securities | Target raised | Hold | $90 → $95 |
| 2026-07-15 | Mizuho | Target raised | Outperform | $100 → $105 |
| 2026-07-13 | RBC Capital | Target raised | Outperform | $100 → $110 |
| 2026-07-08 | Citigroup | Target raised | Buy | $101 → $110 |
| 2026-07-06 | Evercore ISI Group | Target raised | Outperform | $93 → $100 |
| 2026-06-30 | BTIG | Target raised | Buy | $100 → $110 |
Total return (dividends reinvested) (EW)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +17.7% | -22.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +17.8% | -5.0% |
| Volatility (annualized) | 25.5% | 34.0% |
| Max drawdown | -13.2% (Jul 2026→Jul 2026) | -53.0% (Dec 2021→Jul 2024) |
EW revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $1.00B | 57.6% | +12.8% |
| Europe | $439.6M | 25.2% | +16.2% |
| Rest of World | $201.5M | 11.6% | +19.2% |
| Japan | $96.4M | 5.5% | +1.2% |
| Total revenue | $1.74B | 100% | — |
EW revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.26B | 72.3% | +11.3% |
| Surgical | $284.1M | 16.3% | +6.5% |
| Transcatheter Mitral and Tricuspid Therapies | $198.6M | 11.4% | +47.7% |
| Total revenue | $1.74B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
EW suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Medtronic plc (MDT) | “On April 12, 2023, we entered into an intellectual property agreement with Medtronic pursuant to which the parties agreed to a 15-year global covenant not to sue ("CNS") for infringement of certain patents in the structural heart space owned or controlled by each other.” |
Quoted from the company's 10-K filed Feb 25, 2026.
EW analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.74 | $0.75 | -1.3% | $1.68B | 24 |
| Next quarter (ends Dec 2026) | $0.71 | $0.74 | -4.2% | $1.70B | 24 |
| Current fiscal year (ends Dec 2026) | $3.00 | $3.01 | -0.2% | $6.76B | 28 |
| Next fiscal year (ends Dec 2027) | $3.37 | $3.37 | -0.0% | $7.43B | 29 |
EW options: expected move
Options price a move of about ±10.4% (±$9.40) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±3.5% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 46.4% | ±10.4% |
| Dec 18, 2026 | 56 | 36.3% | ±11.4% |
| Jan 15, 2027 | 84 | 33.9% | ±13.0% |
| Feb 19, 2027 | 119 | 34.3% | ±15.6% |
| Mar 19, 2027 | 147 | 34.7% | ±17.5% |
| May 21, 2027 | 210 | 32.8% | ±19.8% |
| Jun 17, 2027 | 237 | 33.0% | ±21.1% |
| Sep 17, 2027 | 329 | 31.7% | ±23.9% |
30-day implied volatility 41.9% vs 25% realized over the last 30 trading days. Put/call ratio (volume) 1.26. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 90.09 |
|---|---|
| Change | ▲ 1.91% (up) |
| Previous Close | USD 88.4 |
| Open | USD 88.64 |
| Day Range | USD 88.28 – 90.18 |
| 52-Week Range | USD 74.66 – 96.29 |
| Volume | 3,054,068 shares |
| Market Cap | $51.93B |
| Exchange | NYQ |
Technical Analysis (EW)
Nexqual's technical model rates EW "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.3 (neutral) |
| vs SMA50 | Above (USD 88.13) |
| MACD | 0.23 (positive) |
Analyst Ratings (EW)
Wall Street analysts rate EW "Buy" based on 30 analysts, with a mean price target of USD 101.39 (range USD 84–110), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 30 |
| Mean Target | USD 101.39 |
| High Target | USD 110 |
| Low Target | USD 84 |
| Buy / Hold / Sell | 23 / 7 / 0 |
Earnings (EW)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.74 |
| Revenue Estimate | $1.68B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.78 vs est 0.74 ▲ beat |
| 2026-03-31 | USD 0.78 vs est 0.73 ▲ beat |
| 2025-12-31 | USD 0.58 vs est 0.62 ▼ miss |
| 2025-09-30 | USD 0.67 vs est 0.59 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (EW)
| Total Revenue | $6.51B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +13.60% |
| Gross Margin | +77.84% |
| Operating Margin | +29.84% |
| Profit Margin | +15.43% |
| ROE | +9.18% |
| Debt / Equity | 0.07 |
| Current Ratio | 4.52 |
| Total Cash | $4.25B |
| Total Debt | $704.40M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.43B (22.0% of revenue) |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financial Health Score (EW)
Nexqual rates Edwards Lifesciences Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:48 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 78%, operating 30% (last 12 months) |
| Balance Sheet | Strong — $4.25B cash and investments vs $599M debt (Jun 2026, SEC), net cash |
| Cash Flow | Strong — FCF $1.43B (last 4 quarters to Jun 2026, SEC), 22% margin |
| Efficiency | Mixed — ROE 9%, ROA 8.4% |
Ownership (EW)
| Insider Ownership | +0.19% |
|---|---|
| Institutional Ownership | +95.67% |
| Shares Outstanding | 576.40M |
| Float | 574.49M |
| Short % of Float | +1.88% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (EW)
Edwards Lifesciences Corporation is led by Bernard J. Zovighian, CEO & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| CEO & Director | Bernard J. Zovighian |
|---|---|
| Corporate Vice President of Strategy & Corporate Development | Donald E. Bobo |
| Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | Daveen Chopra |
| Corporate Vice President of EMEA, Canada, & Latin America | Annette Maria Bruls |
| Corporate VP & CFO | Theodora Mistras |
Major Backers & Investors (EW)
Notable institutional backers of Edwards Lifesciences Corporation include JPMorgan, Wellington Management, Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 3.96% |
| Wellington Management | 2.92% |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 2.26% |
| Ninety One UK Ltd | 2.07% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.12% |
| BlackRock | 10.21% |
| State Street | 4.57% |
| Geode Capital | 2.68% |
| BNY Mellon | 2.45% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
From Edwards Lifesciences Corporation's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- We sell our products in approximately 100 countries, including Germany, Japan, France, United Kingdom ("U.K."), Italy, Canada, China, and Spain.
- Our operations are frequently inspected by the many regulators that oversee medical device manufacturing, including the United States Food and Drug Administration ("FDA"), European Notified Bodies, and other regulatory entities.
- Our differentiated RESILIA tissue technology, with published clinical data showing over 99% freedom from structural valve deterioration through eight years,3 has set the new standard for tissue valve durability.
- To pursue primary research efforts, we have developed alliances with several leading research institutions and universities and also work with leading clinicians around the world in conducting scientific studies on our existing and developing products.
Legal & Regulatory Risks (Item 1A, quoted)
- We spend significant resources to protect and enforce our intellectual property rights, sometimes resulting in expensive and time-consuming litigation that is complex and may ultimately be unsuccessful.
- We and our customers are subject to healthcare legislation and other rigorous governmental regulations and we may incur significant expenses to comply with these regulations.
- Regulatory agencies may refuse to grant approval or clearance, or review and disagree with our interpretation of approvals or clearances, or with our decision that regulatory approval is not required or has been maintained.
- Failure to comply with data privacy and security laws could have a material adverse effect on our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BSX | Boston Scientific Corporation | USD 46.01 | ▲ 3.37% |
| GEHC | GE HealthCare Technologies Inc. | USD 71.42 | ▲ 3.49% |
| DXCM | DexCom, Inc. | USD 78.32 | ▼ 2.42% |
| PHG | Koninklijke Philips N.V. NY Reg | USD 26.92 | ▲ 2.63% |
| SYK | Stryker Corporation | USD 307.08 | ▲ 3.19% |
| MDT | Medtronic plc. | USD 96.59 | ▲ 3.83% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt